当前位置:寻医问药专家网 > 王新军专家个人网站 > 文章列表 > 论文精选 > 文章详情

不同磺脲类对T2DM肾脏结局的影响

标签:糖尿病肾病 论文精选 | 作者:王新军 | 发表时间:2015-04-13 19:20:22

Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.

Abstract AIM: Although several sulphonylureas are widely used in type 2 diabetes (T2D), their differential impacts on long-term major kidney outcomes remain unclear. This study aimed to investigate the effects of the two most commonly prescribed sulphonylureas, glimepiride and gliclazide, on kidney outcomes in patients with T2D. METHODS: A total of 4486 patients treated with either glimepiride or gliclazide for more than 2years were followed for up to 5.5years (median: 4.7years). A propensity score -d on -line characteristics was used to match 1427 patients treated with glimepiride with 1427 gliclazide-treated patients; incidences of end-stage renal disease (ESRD) and sustained doubling of creatinine to>132.6μmol/L (1.5mg/dL) were also compared. RESULTS: In the matched cohort with 12,122 person-years of follow-up, there was no significant difference between groups in risk of ESRD [hazard ratio (HR): 0.57, 95% confidence interval (CI): 0.29-1.12] or doubling of creatinine (HR: 0.74, 95% CI: 0.44-1.26), although there was a trend towards higher risks in the glimepiride group. Subgroup analyses showed that, compared with glimepiride, gliclazide was associated with a lower risk of doubling of creatinine in patients with preserved renal function (glomerular filtration rate≥60mL/min/1.73m2, HR: 0.21, 95% CI: 0.04-0.99) and good glycaemic control (HbA1c


此文章内容仅代表医生观点,仅供参考。涉及用药、治疗等问题请到当地医院就诊,谨遵医嘱!

阅读(513)| (0) | (0) 我要为王新军投票 >
更多

免费咨询在线专家

王新军

副主任医师 副教授

海南医学院附属医院

内分泌科

咨询专家 已回复咨询数:159
预约门诊 已成功预约数:13
给他投票 已获得投票数:11

请务必在就医后进行投票,以保证结果的公平、公正。

温馨提示